Vice President, Preclinical Pharmacology

John is Vice President of Preclinical Pharmacology and Biomarker at Chroma Medicine. Prior to joining Chroma, John was a Senior Director and Head of Preclinical Pharmacology at LogicBio Therapeutics (acquired by Alexion Pharmaceuticals), where he built the preclinical pharmacology department and served as program lead to launch a number of AAV-based therapies for rare diseases. Previously, John led a discovery and translational pharmacology group at Novartis Institutes of Biomedical Research where he had successfully moved multiple programs into Development Candidate and FIH testing. John obtained his doctoral degree and performed post-doctoral research in Department of Medicine, University of Minnesota specializing in regenerative medicine.